Table 2.
Evaluation of adverse event and CTL response
| Case | Dosage (mg) | Frequency of vaccination | Hematological | Non-hematological | RAI | CTL response | Timing of the CTL induction | Clinical and imaging evaluation | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.5 | 88 | None | None | Induration | +++ | Post 9 co. | SD | 25.9 | 32.1 |
| 2 | 0.5 | 19 | None | None | None | − | – | PD | 2.4 | 5.5 |
| 3 | 0.5 | 4 | None | None | None | + | Post 1 co. | PD | 0.9 | 1.0 |
| 4 | 1.0 | 45 | None | None | Induration | +++ | Post 1 co. | SD | 8.1 | 13.1 |
| 5 | 1.0 | 20 | None | None | Erythema | +++ | Post 1 co. | SD | 4.4 | 12.1 |
| 6 | 1.0 | 44 | None | None | Erythema | +++ | Post 1 co. | SD | 10.8 | 25.8 |
| 7 | 3.0 | 38 | None | None | Induration | +++ | Post 1 co. | SD | 10.3 | 77.7 |
| 8 | 3.0 | 34 | None | None | None | +++ | Post 2 co. | SD | 11.0 | 68.4 |
| 9 | 3.0 | 45 | None | None | Induration | +++ | Post 1 co. | SD | 20.8 | 28.7 |